Latest | F'cast | |
---|---|---|
Div Yield | 2.2% | 0.0% |
Div Cover | 2.6 | 2.8 |
Op Mrgn | 18.5% | 32.1% |
ROCE | 60.7% |
Latest | F'cast | |
---|---|---|
P/E | 17.2 | 15.8 |
PEG | 1.3 | 1.6 |
Pr/Revenue | 4.1 | 2.8 |
Pr/Book | 5.4 |
Latest | F'cast | |
---|---|---|
Revenue | 18.0% | -21.0% |
PBT | 26.0% | 57.6% |
EPS | 13.1% | 9.7% |
DPS | 6.9% | -42.8% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 26,617.00 | 3,916.00 | 244.00¢ | 40.4 | 0.3 | +137% | 280.00¢ | 2.8% |
31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,461.7 | n/a | -97% | 287.00¢ | 2.5% |
31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 71.3 | 0.0 | +2,550% | 290.00¢ | 1.9% |
31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.7 | 0.1 | +242% | 290.00¢ | 2.0% |
31-Dec-24 | 54,073.00 | 8,691.00 | 821.00¢ | 17.2 | 1.3 | +13% | 310.00¢ | 2.2% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 57,559.32 | 18,452.99 | 665.24p | 15.8 | 1.6 | +10% | 238.76p | 0.0% |
31-Dec-26 | 61,095.80 | 20,670.40 | 752.91p | 13.9 | 1.1 | +13% | 251.12p | 0.0% |
31-Dec-27 | 64,559.54 | 22,646.47 | 831.15p | 12.6 | 1.2 | +10% | 262.06p | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
Imfinzi recommended in EU for bladder cancer | 27-May-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 23-May-2025 | 10:00 | RNS |
Director Declaration | 21-May-2025 | 13:45 | RNS |
Traded | Action | Notifier | Price | Amount | Value |
---|---|---|---|---|---|
21-May-25 | Transfer From | Pascal Soriot | 0.000p | 8,970 | £0.00 |
30-Apr-25 | Buy | Karen Knudsen | 5,376.72p | 1,400 | £75,274.07 |
06-Mar-25 | Transfer From | Pascal Soriot | 0.000p | 89,962 | £0.00 |
Currency | UK Pounds |
Share Price | 10,382.00p |
Change Today | -102.00p |
% Change | -0.97 % |
52 Week High | 13,276.00 |
52 Week Low | 9,667.00 |
Volume | 243,552 |
Shares Issued | 1,550.64m |
Market Cap | £160,987m |
RiskGrade | 123 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 10 |
Buy | 14 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 20-Feb-25 | 08-Aug-24 |
Paid | 24-Mar-25 | 09-Sep-24 |
Amount | 210.00¢ | 100.00¢ |
Time | Volume / Share Price |
13:23 | 51 @ 10,382.00p |
13:23 | 76 @ 10,382.00p |
13:23 | 60 @ 10,382.00p |
13:23 | 5 @ 10,380.00p |
13:23 | 40 @ 10,380.00p |
You are here: research